Spruce Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Spruce Biosciences, Inc. (SPRB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $50.72 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-03-09
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-06-30 was $1.47.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $3.59.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $50.72, a 5.53% increase from fiscal 2024.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $48.06, a 2812.73% increase from fiscal 2023.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $1.65, a 29.49% decline from fiscal 2022.
- Spruce Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $2.34, a 72.63% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $50.72 10-K · filed 2026-03-09 | ||||
| 2024-12-31 | $48.06 10-K · filed 2026-03-09 | $0.64 10-K · filed 2025-04-15 | |||
| 2023-12-31 | $1.65 10-K · filed 2025-04-15 | ||||
| 2022-12-31 | $2.34 10-K · filed 2024-03-18 | ||||
| 2022-09-30 | $2.34 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | $1.47 10-Q · filed 2022-08-10 | $2.56 10-Q · filed 2022-08-10 | |||
| 2022-03-31 | $3.59 10-Q · filed 2022-05-11 | ||||
| 2021-12-31 | $8.55 10-K · filed 2023-03-16 | ||||
| 2020-12-31 | $3.56 10-K · filed 2022-03-14 | ||||
| 2019-12-31 | $0.98 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |